ADAP Advocacy has published a retrospective white paper examining the promise of the 340B Drug Pricing Program and why reform is in patients' best interest. The paper, titled "340B Program: The Glue That Should Hold Our Healthcare System Together," argues that the program has veered from its original legislative intent by prioritizing provider interests over patient interests. The 340B Program is now the second-largest federal prescription drug program in the United States, behind Medicare Part D.
Brandon M. Macsata, CEO of ADAP Advocacy, stated: "There is an ongoing effort to push for greater transparency across multiple layers of this country's fragmented healthcare system, including hospitals' patient billing practices and pharmacy benefit managers' spread pricing policies. The 340B Program shouldn't be excluded from this broader effort, especially since the ultimate goal is improved program efficiency, leading to greater access to care and treatment for low-income patients."
The calls for greater program transparency are rooted in three central questions: If 340B is designed to expand access and reduce financial burden, then why are patients increasingly unable to afford care? Why is 340B not adequately or even meaningfully addressing this problem? Why is it failing to meet the needs of the uninsured and the underinsured, the very persons it was designed to serve?
The white paper reads, in part: "What started as a support mechanism has grown into something larger, both in terms of dollars and in the depth of the program's integration into the financial aspects of the American healthcare system. For that reason, a healthcare program of this size, magnitude, and importance cannot be entrusted to good faith alone; rather, improved accountability and transparency guardrails are needed to ensure its success and ultimately its intended beneficiaries: patients."
The white paper is available online at https://www.adapadvocacy.org/policycenter/340b. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.
